Human noroviruses are the primary causative agents of acute gastroenteritis and a pressing public health burden worldwide. There are currently no vaccines or small molecule therapeutics available for the treatment or prophylaxis of norovirus infections. Norovirus 3CL protease plays a vital role in viral replication by generating structural and nonstructural proteins via the cleavage of the viral polyprotein. Thus, molecules that inhibit the viral protease may have potential therapeutic value. We describe herein the structure-based design, synthesis, and in vitro and cell-based evaluation of the first class of oxadiazole-based, permeable macrocyclic inhibitors of norovirus 3CL protease. 
INTRODUCTION
Human noroviruses belong to the genus Norovirus in the family Caliciviridae. 1 They are the primary cause of sporadic and epidemic nonbacterial gastroenteritis outbreaks worldwide. [2] [3] [4] [5] Norovirus infection is associated with high morbidity among the elderly and young, as well as immunocompromised patients. 6 The mortality rate among children in developing countries is estimated to exceed 200 000 annually. 7 Of the six norovirus genogroups (GI-VI), GI and GII are associated with human infections, with the GII.4 cluster accounting for 70-80% of norovirus outbreaks worldwide. 8 Devising prophylactic and/or therapeutic interventions for norovirus infection presents a challenge due to the high transmissibility, genetic diversity, environmental stability, and prolonged virus shedding displayed by noroviruses. 9, 10 Furthermore, human noroviruses do not robustly grow in cell culture and only low levels of human norovirus are reported to grow in human B cells. 11 Lastly, there is currently no optimal animal model of the disease; consequently, many aspects of norovirus biology and pathogenesis are poorly understood. 12 The norovirus RNA genome (7.4-7.7 kb) is a positive-sense single stranded genome comprising three open reading frames (ORF1-3) of which ORF1 encodes a 200 kDa polyprotein that is proteolytically cleaved to generate at least six nonstructural proteins: p48, RNA helicase/NTPase, p22, VPg, 3C-like protease (3CLpro), and RNA-dependent RNA polymerase (RdRp). 1, 13 ORF2 and ORF3 encode the norovirus capsid (VP2) and a small basic protein (VP1), respectively. Processing of the polyprotein is effected by the norovirus 3CLpro, a cysteine protease having a chymotrypsin-like fold, an extended binding cleft, and a Cys-His-Glu catalytic triad. [14] [15] [16] The preferred substrate recognition sequence for 3CLpro is -F/Y-X-L-Q-G/A-corresponding to -P 4 -P 3 -P 2 -P 1 -P 1 ′ -, 17 where the P 1 Gln residue determines the primary substrate specificity of the enzyme and X is H, Q, or E. [18] [19] [20] The S 3 subsite displays a degree of plasticity and, therefore, can accommodate a P 3 Gln, His, or Glu. Because processing of the polyprotein by 3CLpro is essential for viral replication, inhibition of 3CLpro is envisaged to be a fruitful avenue of investigation for the discovery of norovirus-specific antivirals, an approach that has been successfully used in the discovery of therapeutics for other viral diseases. 21, 22 We have recently described an array of inhibitors of 3CLpro, [23] [24] [25] [26] [27] including the demonstration of in vivo efficacy by a dipeptidyl inhibitor using a murine norovirus model. 28 We report herein the results of structural, biochemical, and antiviral studies of a novel series of oxadiazole-based cell permeable macrocyclic inhibitors (I) (Figure 1 ) of norovirus 3CLpro.
RESULTS AND DISCUSSION

Inhibitor Design Rationale
There are several disadvantages associated with peptide-derived drugs, including high conformational flexibility, susceptibility to proteolytic degradation, poor membrane permeability, and low oral bioavail-ability. 29, 30 These shortcomings are frequently mitigated through depeptitization. An effective way of depeptitizing a linear peptide is through macrocyclization. [31] [32] [33] [34] The preorganization and structural rigidity that characterize macrocyclic inhibitors frequently enhance pharmacological activity by reducing the entropic penalty associated with binding and, furthermore, increase proteolytic stability. 34 The effect of macrocyclization on cellular permeability and oral bioavailability is less predictable; however, these parameters are expected to be augmented when a macrocycle can engage in intramolecular hydrogen bonding. 35, 36 On the basis of these considerations, we hypothesized that tethering of the P 1 Gln residue, the preferred primary substrate specificity residue of norovirus 3CLpro, with the P 3 residue side chain in an appropriate linear peptide using a 1,3,4-oxadiazole linker would yield a macrocyclic scaffold (I) ( Figure 1 ) potentially capable of participating in intramolecular hydrogen bonding via the ring oxygen or nitrogen atoms, depending on the orientation assumed by the heterocyclic ring. Additional design considerations included ensuring that the ring size of the macrocycle would be optimal in terms of allowing the macrocycle to assume a β-strand conformation, a structural motif recognized by proteases. 37, 38 This is of paramount importance, since a β-strand conformation would allow proper docking/positioning of the inhibitor to the active site which, in turn, would orient correctly the side chains of the P 1 and P 2 residues, thereby maximizing hydrogen bonding and hydrophobic binding interactions. Lastly, the length of the linker and the position of the heterocyclic ring were also anticipated to influence permeability and potency by impacting the conformation of the macrocycle (vide infra).
Chemistry
A convergent approach was used in the synthesis of inhibitors 15-22 (Table 1) . Thus, fragments 4a-f and 6 were first assembled as illustrated in Scheme 1. Fragments 4a-f were synthesized by coupling an appropriate Z-protected carboxylic acid with tert-butyl carbazate using EDCI to yield the Boc-protected hydrazides 1a-e. The Boc protective group was removed via treatment with dry HCl/dioxane, and the resulting hydrazine was coupled to (L)-Boc-glutamic acid α-methyl ester using EDCI/HOBt/DIEA/DMF to yield hydrazides 2a-f. Reaction with p-toluenesulfonyl chloride/DIEA in dry CH 3 CN yielded 1,3,4-removal of the Boc-group to yield 5, which was then coupled to (L)-Boc-Leu using EDCI/ HOBt/DIEA/DMF to form fragment 6. Coupling of fragments 4a-f and 6 generated leucinesubstituted intermediates 7a-c and 7e (Scheme 2). The corresponding cyclohexylalaninesubstituted compounds 7d and 7f-h were prepared by coupling compounds 4a-f to (L)-cyclohexylalanine methyl ester to give esters 13a-d which were hydrolyzed to the corresponding carboxylic acids 14a-d (Scheme 3). Coupling of the acids with (L)-Glu(OBzl) methyl ester yielded compounds 7d and 7f-h. Treatment of compounds 7a-h with H 2 /Pd-C furnished acyclic precursors 8a-h. Subsequent macrolactamization 40 yielded compounds 9a-h which, upon reduction with lithium borohydride, generated the corresponding alcohols 10a-h. Oxidation to aldehydes 15-22 was accomplished using Dess-Martin periodinane, and the synthesized compounds are listed in Table 1 .
Biochemical Studies
The inhibitory activity of compounds 15-22 toward NV 3CLpro, as well as their antinorovirus activity in the NV replicon harboring cells established in Huh-7 cells, was determined as previously described, 26, 28, 41 and the results are tabulated in Table 1 . A graphical dose-dependent inhibition of NV RNA replication by compound 21 is shown in Figure 2 . The screening results shown in Table 1 indicate that (a) in a comparison of compounds 15, 16, and 22 versus compounds 17-21, it is clearly evident that ring size has a profound impact on inhibitory activity and cellular permeability in this series of compounds; (b) with the exception of compound 22, the rest of the inhibitors were relatively wellpermeable to cells and several inhibitors displayed single digit 50% inhibitory concentration (EC 50 ) values in cell based assays (both NV and murine norovirus-1 (MNV-1)); and (c) in contrast to acyclic dipeptidyl transition state inhibitors where the substitution of a P2 Leu residue by a P2 Cha residue results in significant improvement in both IC 50 and EC 50 values, 28 the presence of Cha at P2 did not markedly change potency (compounds 17 and 18; compounds 19 and 20), suggesting that a fruitful strategy for further optimization of potency may necessitate structural modifications in the "cap". In addition, the EC 50 values against NV and MNV-1 in cell culture were well correlated (Table 1) , suggesting the potency (and permeability) of each compound was consistent against multiple noroviruses.
X-ray Crystallographic Studies
In order to establish the precise mechanism of action of inhibitor (I), illuminate the conformation of (I) and the orientation of the linker, as well as obtain structural information that can be used to guide the optimization of pharmacological activity, high resolution X-ray crystal structures of inhibitors 21 and 22 with NV 3CLpro were determined. Examination of the active site revealed the presence of prominent electron density in subunit A consistent with inhibitors 21 and 22 covalently bound to Cys 139 and the cyclohexyl alanine side chain nestled into the hydrophobic S 2 subsite 17 ( Figure 3 ). However, for inhibitor 21, the majority of the macrocycle was disordered and could not be modeled. This disorder was consistently observed from approximately 10 X-ray diffraction data sets obtained for this complex. A surface representation of NV 3CLpro, colored by residue type, with inhibitor 22 is shown in Figure 4 .
The hydrogen-bonding interactions between NV 3CLpro and inhibitors 21 and 22 are shown in Figure 5 and include multiple hydrogen bonds between Ala160, Gln 110, and Ala158 and the inhibitor backbone which serve to correctly position the inhibitor in the active site cleft. Critical hydrogen bonds involving the P1 Gln side chain and the His157 and Thr134 residues are also clearly evident for inhibitor 22. However, hydrogen bonding to Thr134 was not observed for the complex with inhibitor 21 due to disorder of the residues between Leu132 and Gly137. These binding interactions, as well as the flexible backbone of the T123-G133 loop, are postulated to play a critical role in enzyme recognition. 42 The lack of cellular permeability of inhibitor 22 is supported by the absence of any intramolecular hydrogen bonds with the oxadiazole ring; however, permeability involves the interplay of many factors besides intramolecular hydrogen bonding. Notably, interactions between inhibitor 21 and Thr134 were not observed, since the loop of NV 3CLpro spanning Gly133-Pro136 was consistently disordered. Thus, it seems that the macrocycle ring size may play a role in forming optimal hydrogen bond interactions with NV 3CLpro. Surprisingly, decreasing the macrocycle ring from 21 atoms (inhibitor 22) to 20 atoms (inhibitor 21) results in more disorder of the inhibitor and nearby residues of NV 3CLpro. In order to gain insight and understanding into the structural determinants that impact potency and cellular permeability, herculean efforts were expended in obtaining high resolution X-ray crystal structures of permeable inhibitors 18-20, albeit without success. Although crystals were obtained for NV 3CLpro cocrystallized with inhibitors 18-20, these samples only yielded weak X-ray diffraction properties even after optimization of the crystallization conditions. Finally, the crystallographic data indicate that the oxadiazole-based macrocyclic inhibitors weaken all H-bonding prospects for this pharmacophore element.
In an effort to correlate the crystal structures with the data provided in Table 1 , the structures of NV 3CLpro were superimposed using secondary structure matching with GESAMT. 43 Not surprising, the overall structures of the NV 3CLpro were very similar to an rmsd of 0.54 Å between Cα atoms (158 residues). In order to conduct a more direct analysis of the inhibitors, the disordered portion of the macrocycle for inhibitor 21 was modeled in an idealized position and compared with inhibitor 22 ( Figure 6 ). Notably, the shorter ring size of inhibitor 21 appears to move the inhibitor slightly away from the loop containing Thr134 which precludes formation of a hydrogen bond and disorder of residues Gly133-Pro136 in the nearby loop. However, inhibitor 22 is able to stabilize this loop region by formation of a hydrogen bond with Thr134 due to the larger ring size. This perhaps explains the observed difference in the IC 50 values (Table 1) , as inhibitor 22 is able to form an extra hydrogen bond relative to the other inhibitors. Further shortening of the macrocycle ring size (inhibitors 15-20) would likely move the inhibitor further away from Thr134 and prevent formation of hydrogen bonds with the loop and result in disorder of these residues. This may also explain why the crystals obtained with inhibitors 18-20 produced poor diffraction, as the dynamic conformations of the nearby loop could potentially prevent formation of wellordered crystals. Conversely, the shorter macrocycle ring size appears to be more conducive to permeability, although binding to the NV 3CLpro target is slightly weakened.
CONCLUSIONS
There is currently a dire need for the development of norovirus-specific therapeutics and prophylactics for the management of norovirus infections. The studies described herein disclose the structure-based design of the first series of oxadiazole-based permeable macrocyclic inhibitors of norovirus 3CL protease. Insights gained from these studies have laid a solid foundation for conducting further preclinical studies focused on the optimization of potency and pharmacokinetics.
EXPERIMENTAL SECTION General
Reagents and dry solvents were purchased from various chemical suppliers (Aldrich, Acros Organics, Chem-Impex, TCI America, Oakwood Chemicals, Bachem, and Fisher) and were used as obtained. Silica gel (230-450 mesh) used for flash chromatography was purchased from Sorbent Technologies (Atlanta, GA). Thin layer chromatography was performed using Analtech silica gel plates. The 1 H spectra were recorded in CDCl 3 or DMSO-d 6 on a Varian XL-400 NMR spectrometer. High resolution mass spectrometry (HRMS) experiments were performed at the University of Kansas Mass Spectrometry lab using an LCT Premier mass spectrometer (Waters, Milford, MA) equipped with a time-of-flight mass analyzer and an electrospray ion source. Visualization was accomplished using UV light and/or iodine. Reverse phase HPLC was utilized to determine the purity of the final compounds (>95% purity).
Peptide Coupling Reactions. Synthesis of Compounds 1a-e. General Procedure
To a stirred solution of N-protected amino acid derivative (112 mmol) in dry CH 2 Cl 2 (400 mL) was added EDCI (135 mmol), and the reaction mixture was stirred for 30 min at ambient temperature. t-Boc hydrazide (196 mmol) was added, and the reaction mixture was stirred for 18 h at room temperature. The solution was washed with 5% aqueous HCl (2 × 100 mL), saturated NaHCO 3 (2 × 100 mL), and brine (100 mL). The organic phase was dried over anhydrous Na 2 SO 4 , filtered, and concentrated to yield the desired compounds. 
Synthesis of Oxadiazole Compounds 3a-f. General Procedure
To a solution of compound 2 (11.0 g, 22.89 mmol) in dry acetonitrile (275 mL) were added p-toluenesulfonyl chloride (13.09 g, 68.67 mmol, 3.0 equiv), DIEA (5.91 g, 45.78 mmol), and the reaction mixture was stirred for 16 h at room temperature while monitoring the reaction by TLC. The solvent was removed in vacuo, and the residue was partitioned between ethyl acetate (300 mL) and 5% aqueous HCl (2 × 100 mL). The ethyl acetate layer was further washed with saturated aqueous NaHCO 3 (2 × 100 mL), followed by saturated NaCl (100 mL). The organic layer was dried over anhydrous Na 2 SO 4 , filtered, and concentrated. The crude product was purified using flash chromatography to yield the desired oxadiazole derivatives 3a-f.
Methyl (S)-3-(5-((((Benzyloxy)carbonyl)amino)methyl)-1,3,4-oxadiazol-2-yl)-2-((tertbutoxycarbonyl)amino)propanoate (3a)
Oil, yield (70% 
Methyl (S)-4-(5-((((Benzyloxy)carbonyl)amino)methyl)-1,3,4-oxadiazol-2-yl)-2-((tertbutoxycarbonyl)amino)butanoate (3b)
Oil, yield (73% 
Methyl (S)-4-(5-(2-(((Benzyloxy)carbonyl)amino)ethyl)-1,3,4-oxadiazol-2-yl)-2-((tertbutoxycarbonyl)amino)butanoate (3c)
Oil, yield (75% 
Methyl (S)-4-(5-(3-(((Benzyloxy)carbonyl)amino)propyl)-1,3,4-oxadiazol-2-yl)-2-((tertbutoxycarbonyl)amino)-butanoate (3d)
Synthesis of Acids 4a-f. General Procedure
A solution of ester 3 (20 mmol) in THF (30 mL) was treated with 1 M LiOH in aqueous THF (40 mL). The reaction mixture was stirred for 3 h at room temperature, and the disappearance of the ester was monitored by TLC. Most of the solvent was evaporated off, and the residue was diluted with water (25 mL). The solution was acidified to pH ≈ 3 using 5% hydrochloric acid (20 mL), and the aqueous layer was extracted with ethyl acetate (3 × 100 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated to yield the desired compound.
(S)-3-(5-((((Benzyloxy)carbonyl)amino)methyl)-1,3,4-oxadia-zol-2-yl)-2-((tertbutoxycarbonyl)amino)propanoic Acid (4a)
Yield ( 
(S)-4-(5-((((Benzyloxy)carbonyl)amino)methyl)-1,3,4-oxadia-zol-2-yl)-2-((tertbutoxycarbonyl)amino)butanoic Acid (4b)
Oil, yield (94% 
(S)-4-(5-(3-(((Benzyloxy)carbonyl)amino)propyl)-1,3,4-oxa-diazol-2-yl)-2-((tertbutoxycarbonyl)amino)butanoic Acid (4d)
Oil, yield (96% 
(S)-4-(5-(4-(((Benzyloxy)carbonyl)amino)butyl)-1,3,4-oxadia-zol-2-yl)-2-((tertbutoxycarbonyl)amino)butanoic Acid (4e)
Oil, yield (95% 
(S)-4-(5-(5-(((Benzyloxy)carbonyl)amino)pentyl)-1,3,4-oxa-diazol-2-yl)-2-((tertbutoxycarbonyl)amino)butanoic Acid (4f)
Oil, yield (95%). 1 
Synthesis of Amino Acid Methyl Esters 5. General Procedure
To a solution of (L)-Boc-Glu(OBzl)-OH (16.86 g, 50 mmol) in dry DMF (100 mL) was added NaHCO 3 (25.2 g, 300 mmol) followed by methyl iodide (14.2 g, 100 mmol). The reaction mixture was stirred for 72 h at room temperature. The progress of the reaction was monitored by TLC. The solids were filtered off, and the solvent was removed in vacuo. The residue was partitioned between ethyl acetate (250 mL) and water (2 × 75 mL). The ethyl acetate layer was washed with saturated NaCl (75 mL) and the organic layer was dried over anhydrous Na 2 SO 4 , filtered and concentrated to yield an oily product, which was purified by flash chromatography to yield compound 5 as a colorless oil.
5-Benzyl 1-Methyl (tert-Butoxycarbonyl)glutamate (5)
Oil, yield (85% 
Synthesis of Compound 6. General Procedure
To a solution of (L)-Boc-Leu-OH (54.87 mmol) in dry DMF (100 mL) were added EDCI (12.83 g, 66.94 mmol, 1.3 equiv), HOBt (10.27 g, 66.94 mmol, 1.3 equiv), and the reaction mixture was stirred for 30 min at room temperature. In a separate flask, a solution of deprotected compound 5 (15.8 g, 54.87 mmol) in dry DMF (100 mL) cooled to 0-5 °C was treated with diisopropylethylamine (DIEA) (28.36 g, 219.48 mmol, 4.0 equiv), stirred for 30 min, and then added to the above reaction mixture. The solution was stirred for 16 h while monitoring the reaction by TLC. The solvent was removed and the residue was partitioned between ethyl acetate (300 mL) and 5% aqueous HCl (2 × 120 mL). The ethyl acetate layer was further washed with aqueous NaHCO 3 (2 × 120 mL), followed by saturated NaCl (120 mL). The organic layer was dried over anhydrous Na 2 SO 4 , filtered, and concentrated to yield a yellow oil which was purified by flash chromatography to yield an oily product which was deblocked with 4 M HCl in dioxane to yield compound 6.
Synthesis of Compounds 7a-h. General Procedure
To a solution of compound 4 (10.0 g, 22.29 mmol) in dry DMF (100 mL) was added EDCI (5.55 g, 28.98 mmol, 1.3 equiv), and the mixture was stirred for 30 min at room temperature.
In a separate flask, a solution of deprotected compound 6 (7.6 g, 22.29 mmol) in dry DMF (100 mL) cooled to 0-5 °C was treated with diisopropylethylamine (DIEA) (11.52 g, 89.16 mmol, 4.0 equiv), stirred for 30 min, and then added to the reaction mixture above. The solution was stirred for 16 h while monitoring the reaction by TLC, and the solvent was removed in vacuo. The residue was partitioned between (400 mL) and 5% aqueous HCl (2 × 120 mL). The ethyl acetate layer was further washed with saturated aqueous NaHCO 3 (2 × 120 mL), followed by saturated NaCl (120 mL). The organic layer was dried over anhydrous Na 2 SO 4 , filtered, and concentrated. The crude product was purified by flash chromatography to yield the desired products.
5-Benzyl 1-Methyl ((S)-3-(5-((((Benzyloxy)carbonyl)amino)-methyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)amino)-propanoyl)-L-leucyl-L-glutamate (7a)
5-Benzyl 1-Methyl ((S)-4-(5-((((Benzyloxy)carbonyl)amino)-methyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)amino)-butanoyl)-L-leucyl-L-glutamate (7b)
5-Benzyl 1-Methyl ((S)-4-(5-(3-(((Benzyloxy)carbonyl)-amino)propyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)-amino)butanoyl)-L-leucyl-L-glutamate (7e)
Hydrogenolysis of Benzyl Esters 8a-h. General Procedure
To a solution of benzyl ester 7 (12.0 g, 15.09 mmol) in methanol 120 mL (10 mL/g of ester) was added 10% palladium on carbon (0.80 g, 50 mol %), and the mixture was shaken on a Parr hydrogenator for 8 h under 40 atm of H 2 while monitoring the reaction by TLC. The reaction mixture was filtered through Celite, and the Celite bed was washed with methanol. The filtrate was concentrated under reduced pressure to yield compounds 8a-h. (6S,9S,12S)-6-(2-(5-(2-Aminoethyl)-1,3,4-oxadiazol-2-yl)-ethyl)-9-(cyclohexylmethyl)-12 
(6S,9S,12S)-6-(2-(5-(4-Aminobutyl)-1,3,4-oxadiazol-2-yl)-ethyl)-9-(cyclohexylmethyl)-12-(methoxycarbonyl)-2,2-di-methyl-4,7,10-trioxo-3-oxa-5,8,11-triazapentadecan-15-oic Acid (8g)
Yield (91%), mp 111-113 °C. 1 
(6S,9S,12S)-6-(2-(5-(4-Aminobutyl)-1,3,4-oxadiazol-2-yl)-ethyl)-9-(cyclohexylmethyl)-12-(methoxycarbonyl)-2,2-di-methyl-4,7,10-trioxo-3-oxa-5,8,11-triazapentadecan-15-oic Acid (8h)
Yield (96%), mp 103-106 °C. 1 
Synthesis of Macrocyclic Oxadiazole Esters 9a-h. General Procedure
To a solution of compound 8 (2.0 g, 3.5 mmol) in dry DMF (750 mL) were added EDCI (0.87 g, 4.55 mmol, 1.3 equiv), HOBt (0.7 g, 4.55 mmol, 1.3 equiv), DIEA (1.35 g, 10.5 mmol, 3.0 equiv), and the mixture was stirred for 18 h at room temperature while monitoring the reaction by TLC. The solvent was removed, and the residue was partitioned between ethyl acetate (200 mL) and 10% citric acid (2 × 50 mL). The ethyl acetate layer was further washed with saturated aqueous NaHCO 3 (2 × 50 mL), followed by saturated NaCl (50 mL). The organic layer was dried over anhydrous Na 2 SO 4 , filtered, and concentrated. The crude product was purified by flash chromatography to yield compounds 9a-h.
Methyl (7S,10S,13S)-13-((tert-Butoxycarbonyl)amino)-10-isobutyl-4,9,12-trioxo-3,8,11-triaza-1(2,5)-oxadiazolacyclote-tradecaphane-7-carboxylate (9a)
Yield (60%), mp 160-163 °C. 1 
Methyl (7S,10S,13S)-13-((tert-Butoxycarbonyl)amino)-10-isobutyl-4,9,12-trioxo-3,8,11-triaza-1(2,5)-oxadiazola-cyclopentadecaphane-7-carboxylate (9b)
Yield (67%), mp 177-180 °C. 1 
Methyl (8S,11S,14S)-14-((tert-Butoxycarbonyl)amino)-11-(cyclohexylmethyl)-5,10,13-trioxo-4,9,12-triaza-1(2,5)-oxadiazolacyclohexadecaphane-8-carboxylate (9d)
Methyl (9S,12S,15S)-15-((tert-Butoxycarbonyl)amino)-12-(cyclohexylmethyl)-6,11,14-trioxo-5,10,13-triaza-1(2,5)-oxadiazolacycloheptadecaphane-9-carboxylate (9f)
Yield (65%), mp 177-180 °C. 1 
Methyl (4S,7S,10S)-4-((tert-Butoxycarbonyl)amino)-7-(cyclohexylmethyl)
-
Methyl (4S,7S,10S)-4-((tert-
Synthesis of Alcohols 10a-h. General Procedure
To a solution of ester 9 (3.25 mmol) in anhydrous THF (25 mL) was added dropwise lithium borohydride (2 M in THF, 4.9 mL, 9.75 mmol) followed by absolute ethyl alcohol (15 mL), and the reaction mixture was stirred at room temperature overnight. The reaction mixture was then acidified by adding 1.5 M potassium bisulfate until the pH of the solution was ~3.
Removal of the solvent left a residue which was taken up in ethyl acetate (150 mL). The organic layer was washed with brine (25 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to yield compounds 10a-h. 10-isobutyl-4,9,12-trioxo-3,8,11-triaza-1(2,5) ((8S,11S,14S)-11-(Cyclohexylmethyl)-8-(hydroxymethyl)-5, 10, 13-trioxo-4, 9, 12 
tert-Butyl ((7S,10S,13S)-7-(Hydroxymethyl)-
tert-Butyl
Synthesis of Compounds 13a-d. General Procedure
To a solution of compound 4 (12.0 g, 26.75 mmol) in dry DMF (120 mL) were added EDCI (6.7 g, 34.78 mmol, 1.3 equiv), HOBt (5.29 g, 34.78 mmol, 1.3 equiv), and the mixture was stirred for 30 min at room temperature. In a separate flask, a solution of (L)-cyclohexyl alanine methyl ester hydrochloride 12 (5.93 g, 26.75 mmol) in dry DMF (100 mL) cooled to 0-5 °C was treated with diisopropylethylamine (13.83 g, 107 mmol, 4.0 equiv), stirred for 30 min, and then added to the reaction mixture above. The solution was stirred for 16 h while monitoring the reaction by TLC. The solvent was removed, and the residue was partitioned between ethyl acetate (300 mL) and 5% aqueous HCl (2 × 120 mL). The ethyl acetate layer was further washed with saturated NaHCO 3 (2 × 120 mL), followed by saturated NaCl (120 mL). The organic layer was dried over anhydrous Na 2 SO 4 , filtered, and concentrated. The crude product was purified by flash chromatography to yield compounds 13a-d.
Methyl (S)-2-((S)-4-(5-(2-(((Benzyloxy)carbonyl)amino)ethyl)-1,3,4-oxadiazol-2-yl)-2-((tertbutoxycarbonyl)amino)-butanamido)-3-cyclohexylpropanoate (13a)
Oil, yield (80%). 1 
Methyl (S)-2-((S)-4-(5-(3-(((Benzyloxy)carbonyl)amino)-propyl)-1,3,4-oxadiazol-2-yl)-2-((tertbutoxycarbonyl)amino)-butanamido)-3-cyclohexylpropanoate (13b)
Oil, yield (81%). 1 
Methyl (S)-2-((S)-4-(5-(4-(((Benzyloxy)carbonyl)amino)-butyl)-1,3,4-oxadiazol-2-yl)-2-((tertbutoxycarbonyl)amino)-butanamido)-3-cyclohexylpropanoate (13c)
Oil, yield (81% 5-(((Benzyloxy)carbonyl)amino)-pentyl)-1,3,4-oxadiazol-2-yl)-2-((tertbutoxycarbonyl) 
Methyl (S)-2-((R)-4-(5-(
Synthesis of Compounds 14a-d. General Procedure
A solution of ester 13 (25 mmol) in THF (40 mL) was treated with 1 M LiOH in aqueous ethanol (50 mL). The reaction mixture was stirred for 3 h at room temperature, and the disappearance of the ester was monitored by TLC. Most of the solvent was evaporated off, and the residue was diluted with water (25 mL). The solution was acidified to pH ≈ 3 using 5% hydrochloride acid (25 mL), and the aqueous layer was extracted with ethyl acetate (3 × 100 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated to yield compounds 14a-d.
(S)-2-((S)-4-(5-(2-(((Benzyloxy)carbonyl)amino)ethyl)-1,3,4-oxadiazol-2-yl)-2-((tertbutoxycarbonyl)amino)butanamido)-3-cyclohexylpropanoic Acid (14a)
(S)-2-((R)-4-(5-(4-(((Benzyloxy)carbonyl)amino)butyl)-1,3,4-oxadiazol-2-yl)-2-((tertbutoxycarbonyl)amino)butanamido)-3-cyclohexylpropanoic Acid (14c)
Oil, yield (98% 
5-Benzyl 1-Methyl ((S)-2-((S)-4-(5-(4-(((Benzyloxy)carbonyl)-amino)butyl)-1,3,4-oxadiazol-2-yl)-2-((tert-butoxycarbonyl)-amino)butanamido)-3-cyclohexylpropanoyl)-L-glutamate (7g)
Synthesis of Aldehydes 15-22. General Procedure
Compound 10 (0.95 mmol) was dissolved in anhydrous dichloromethane (30 mL) under a nitrogen atmosphere and cooled to 0 °C. Dess-Martin periodinane reagent (1.21 g, 2.85 mmol, 3.0 equiv) was added to the reaction mixture with stirring. The ice bath was removed, and the reaction mixture was stirred at room temperature for 3 h (monitoring by TLC indicated complete disappearance of the starting material). A solution of 40 mM sodium thiosulfate in saturated aqueous NaHCO 3 (50 mL) was added, and the solution was stirred for another 15 min. The aqueous layer was removed, and the organic layer was washed with sodium bicarbonate (25 mL), water (2 × 25 mL), and brine (25 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated. The yellow residue was purified by flash chromatography (silica gel/methylene chloride/ethyl acetate/methanol) to yield aldehydes 15-22. 
tert-Butyl ((7S
,
Enzyme Assays and Inhibition Studies
These studies were carried out as described previously. 26, 28, 41 The NV 3CLpro fluorescence resonance energy transfer (FRET) assay was performed using a fluorogenic substrate (Edans-DFHLQGP-Dabcyl) which is derived from the cleavage sites on NV polyproteins. Methods for FRET assay and determination of the IC 50 values of protease inhibitors against 3CLpro were described previously by our lab. 26, 28, 41 
Antiviral Assays
Each compound was evaluated for anti-3CLpro effects up to 100 μM. For the cell based assay, 1 day old HG23 cells (NV replicon harboring cells) were treated with various concentrations (1.0-100 μM) of each compound and incubated for 48 h. Then total RNA was extracted from cells for qRT-PCR for norovirus and β-actin. The EC 50 and EC 90 (the 50% and 90% inhibitory concentration in cell based assay, respectively) of each compound were calculated by the % reduction of RNA levels to Mock-treated cells after normalization with β-actin levels. Each compound was also tested against MNV-1. Confluent RAW267.4
was inoculated with MNV-1 at a MOI of 0.05, and at the same time, various concentrations (1.0-100 μM) of each compound were added to the medium. Virus infected cells were further incubated for 72 h until extensive cytopathic effects (CPE) progress. The EC 50 of each compound was determined by 50% inhibition of CPE progress (cell death) by each compound at 48 h using a CytoTox96 nonradioactive cytotoxicity assay kit (Promega, Madison, WI) following the manufacturer's instructions. Cell cytotoxicity for each compound in HG23 cells was also measured by the cytotoxicity assay kit with serial dilution up to 100 μM. The CC 50 (the 50% cytotoxic concentration) was determined for each compound. The IC 50 , EC 50 , or CC 50 values were determined by at least two independent experiments.
X-ray Crystallographic Studies. Crystallization and Data Collection
Purified norovirus 3CL protease (3CLpro) in 100 mM NaCl, 50 mM PBS, pH 7.2, 1 mM DTT at a concentration of 10 mg/mL was used for the preparation of the enzyme:22 complex. Stock solutions of 100 mM 21 and 22 were prepared in DMSO and the 3CLpro:inhibitor complex was prepared by mixing 7 μL of the inhibitors (3 mM) with 243 μL (0.49 mM) of 3CLpro and incubating on ice for 1 h. The buffer was exchanged to 100 mM NaCl, 20 mM Tris, pH 8.0, using a Zeba spin desalting column (MWCO = 7 kDa, Life Technologies), and the sample was concentrated to 10.0 mg/mL for crystallization screening.
All crystallization experiments were conducted using a Compact Jr. (Rigaku Reagents) sitting drop vapor diffusion plates at 20 °C and equal volumes of protein and crystallization solution equilibrated against 75 μL of the latter. Crystals were obtained from the from the Index HT screen (Hampton Research). Prismatic crystals of NV 3CLpro:21 were obtained in 2 days from condition E9 (30% v/v pentaerythritol ethoxylate (15/4 EO/OH), 50 mM BisTris, pH 6.5, 50 mM ammonium sulfate). Crystals of NV 3CLpro:22 displaying a needle morphology were obtained in 2-3 days condition H12 (30% (w/v) PEG 2000 MME, 150 mM potassium bromide). Samples were cryoprotected in a fresh drop crystallant for NV 3CLpro:21 and 80% crystallization solution/20% glycerol for NV 3CLpro:22, before storing in liquid nitrogen. X-ray diffraction data were collected at the Advanced Photon Source beamline 17-ID using a Dectris Pilatus 6M pixel array detector.
Structure Solution and Refinement
Intensities were integrated using XDS, 44, 45 and the Laue class analysis and data scaling were performed with Aimless 46 which suggested that the highest probability Laue class was 2/m (C2) for NV 3CLpro:21 and mmm (P2 1 2 1 2 1 ) for NV 3CLpro:22. Structure solution was conducted by molecular replacement with Phaser 47 using a previously determined isomorphous structure of inhibitor bound norovirus 3CLpro (PDB code 3UR9) as the search model. Structure refinement and manual model building were conducted with Phenix 48 and Coot, 49 respectively. Disordered side chains were truncated to the point for which electron density could be observed. All atoms were refined with anisotropic atomic displacement parameters for NV 3CLpro:21. Structure validation was conducted with Molprobity, 50 and figures were prepared using the CCP4MG package. 51 Coordinates and structure factors were deposited to the wwPDB with the accession codes 5DGJ (NV 3CLpro:21) and 5DG6 (NV 3CLpro:22).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. Superposition of NV 3CLpro complexes with inhibitors 21 (green) and 22 (magenta). The disordered portion in inhibitor 21 was modeled in an idealized geometry for comparison with inhibitor 22.
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